SCHEMBL3989708

SCHEMBL3989708

COc1nn(Cc2ccc(F)cc2)c(=O)c2c(OCc3ccccc3)c3n(c12)CCN(C)C3=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.40
POLB P06746 1/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.38
FAAH O00519 1/20 0.38
MGLL Q99685 1/20 0.38
TSHR P16473 3/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
USP2 O75604 1/20 0.36
CYP2C9 P11712 1/20 0.36
GRM5 P41594 2/20 0.35
GRM3 Q14832 1/20 0.35
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35
PKM P14618 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3981450 0.90 SMN1; SMN2 (0.43) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3987185 0.90 SMN1; SMN2 (0.40) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3982263 0.90 SMN1; SMN2 (0.40) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3985459 0.90 SMN1; SMN2 (0.40) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3985405 0.88 SMN1; SMN2 (0.39) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3983923 0.87 SMN1; SMN2 (0.38) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3985775 0.85 ADORA1 (0.37) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3982232 0.85 ALDH1A1 (0.38) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3991465 0.84 ALDH1A1 (0.37) SMN1; SMN2POLBRECQLLMNAL3MBTL1
SCHEMBL3985497 0.83 PKM (0.37) CNR1CNR2PKMNPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
EP-1756114-A2 HIV INTEGRASE INHIBITORS Merck and Co., Inc. (US) 2007-02-28 EP disclosed
WO-2005110414-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP SMN1; SMN2 4264/4885POLB 80/4885RECQL 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.